Close Menu
Bharat Speaks
  • Trending
  • Motivation
  • Health
  • Education
  • Development
  • About Us
What's Hot

​NCP-SP Agrees in Principle to 50% Lok Sabha Seat Hike and Women’s Reservation Proposal

November 16, 2026

​No Prosecution for Reapplying After Electoral Roll Deletion in SIR, EC Tells Supreme Court

November 16, 2026

​Bihar Minister Ashok Choudhary Faces MLC Disqualification Threat Over Assistant Professor Post

November 16, 2026
Facebook X (Twitter) Instagram
Facebook X (Twitter) Instagram
Bharat Speaks
Subscribe
  • Trending
  • Motivation
  • Health
  • Education
  • Development
  • About Us
Bharat Speaks
Home»Health»A Cancer Drug Heads to Space: Axiom-4 Mission to Test Rebecsinib in Microgravity
Health

A Cancer Drug Heads to Space: Axiom-4 Mission to Test Rebecsinib in Microgravity

BharatSpeaksBy BharatSpeaksJune 26, 2025No Comments2 Mins Read
Facebook Twitter LinkedIn Telegram WhatsApp Email
Share
Facebook Twitter LinkedIn Pinterest Email

In a major leap for biomedical science, the upcoming Axiom Mission 4 (Ax-4) will carry the first FDA-approved investigational cancer drug, Rebecsinib, into space for testing aboard the International Space Station (ISS). The mission, backed by commercial spaceflight leader Axiom Space, is set to explore how microgravity accelerates cancer research—potentially shaving years off drug development timelines.

Cancer Research Enters Microgravity

Developed by Aspera Biomedicines in collaboration with the UC San Diego Sanford Stem Cell Institute, Rebecsinib is a first-in-class ADAR1 splicing inhibitor designed to target cancer stem cells. The drug previously demonstrated success in earlier Axiom missions—Ax-2 and Ax-3—by outperforming existing therapies like Fedratinib in limiting the growth of cancer organoids.

What makes this mission distinctive is the experimental advantage provided by microgravity. In orbit, tumor organoids—3D clusters that mimic actual tumors—can double in size in just 10 days, giving scientists rapid insights into how the drug behaves in complex biological systems.

A Mission of Many Firsts

This is the first time a drug with FDA Investigational New Drug (IND) approval will be tested in space under a commercial biomedical payload. According to the team, the focus will now expand to evaluating Rebecsinib’s effect on triple-negative breast cancer, a notoriously aggressive and hard-to-treat form of cancer.

“This marks a historic milestone—not just in space exploration, but in the fusion of space and human health research,” said Tejpaul Bhatia, Chief Revenue Officer of Axiom Space.

The findings from Ax-4 could significantly inform clinical trials back on Earth, helping accelerate the regulatory pipeline and improve targeted cancer therapies.

A Broader Research Horizon

The Ax-4 mission isn’t only about cancer. It will carry over 60 experiments from 31 countries, spanning fields such as diabetes, immune system modulation, stem cell studies, plant biology, and space-induced physiological changes.

The mission underscores a growing trend: using the ISS as a high-speed incubator for medical innovation. Axiom Space, in partnership with NASA and international agencies, has positioned itself as a key player in the next wave of science-driven commercial spaceflight.

📲 Join Our WhatsApp Channel
Algoritha Registration
Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
Previous ArticleIndia’s First International Potato Centre to Open in Agra: A Game-Changer for Farmers and Food Security
Next Article Broken Curriculum, Missing Doctors”: NITI Aayog’s Paul Sounds Alarm
BharatSpeaks

Related Posts

Felix Hospital Noida Successfully Performs Robotic Double Knee Replacement on 72-Year-Old Woman

November 12, 2026

Health Insurance Explained: Benefits, Types and How to Choose the Right Plan

November 12, 2026

Losing Muscle? Here’s How It Could Increase Your Diabetes Risk

November 12, 2026
Add A Comment
Leave A Reply Cancel Reply

Top Posts

Subscribe to Updates

Get the latest sports news from SportsSite about soccer, football and tennis.

Welcome to BharatSpeaks.com, where our mission is to keep you informed about the stories that matter the most. At the heart of our platform is a commitment to delivering verified, unbiased news from across India and beyond.

We're social. Connect with us:

Facebook X (Twitter) Instagram YouTube
Top Insights
Get Informed

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

© 2026 Bharat Speaks.
  • Trending
  • Motivation
  • Health
  • Education
  • Development
  • About Us

Type above and press Enter to search. Press Esc to cancel.